Pharma

Your Article Summary

See Latest Articles

Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Sanofi-aventis, 09/14/09

Sanofi–aventis and Regeneron Pharmaceuticals, Inc. announced the discontinuation of the Phase 3 trial that evaluated aflibercept plus gemcitabine versus placebo plus gemcitabine for the first–line treatment of metastatic pancreatic cancer, based on the recommendations by an Independent Data Monitoring Committee. As part of a planned interim efficacy analysis, the IDMC determined that the addition of aflibercept to gemcitabine would be unable to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to placebo plus gemcitabine in this study.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials